Our findings provide evidence that rare loss-of-function germline variants in RAD51B (found in 9/3422 [0.26%] consecutive breast or ovarian cancer cases who consented for germline analysis) are indeed associated with an increased risk of breast and ovarian cancer among women. This evidence concerns the gene RAD51B and ovarian cancer.